• Publications
  • Influence
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a
BACKGROUND REP 2139 clears circulating hepatitis B virus (HBV) surface antigen (HBsAg), enhancing the restoration of functional control of HBV infection by immunotherapy. We assessed the safety andExpand
  • 74
  • 2
Update on the Safety and Efficacy of REP 2139 Monotherapy and Subsequent Combination Therapy with Pegylated Interferon Alpha-2A in Caucasian Patients with Chronic HBV/HDV Co-Infection
1. Replicor Inc. Montreal, Canada; 2. Department of Infectious Diseases, N. Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of Moldova; 3. Toma Ciorba Infectious ClinicalExpand
  • 16
  • 2
Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month
REP 2139 is a nucleic acid polymer which blocks the assembly / secretion of HBV subviral particles1 and additionally binds to the small and large forms of HDAg2 (see Fig. 1). In the previous REP 301Expand
  • 13
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
BACKGROUND & AIMS Nucleic acid polymers (NAPs) inhibit assembly and secretion of hepatitis B virus (HBV) subviral particles. We performed an open-label, phase 2 study of the safety and efficacy ofExpand
  • 17
  • PDF
Safety and efficacy of REP 2139 and pegylated interferon alfa-2 a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection ( REP 301 and REP 301-LTF ) : a
Replicor, Montreal, QC, Canada (M Bazinet MD, A Vaillant PhD); Department of Infectious Diseases, State University of Medicine and Pharmacy ‘Nicolae Testemitanu’, Chișinău, Moldova (Prof V Pântea MD,Expand
  • 5
  • PDF